Podcasts about pfizer inc

Episode 372 April 26, 2025   Welcome to The Weekly Option, a weekly program that offers practical trades and discussion for beginners and professionals alike.   The topic of the week is context.     In this week's show, we will cover the trades from last week on NIO Inc, Pfizer Inc, and Lyft Inc.… Continue reading Episode 372 Trading podcast for stock options April 26, 2025

Send us a textDr. Martin Brenner, DVM, Ph.D. is Chief Executive Officer and Chief Scientific Officer of iBio ( https://ibioinc.com/team/martin-brenner-dvm-ph-d/ ), a biotech company developing the next generation of cardiometabolic and obesity medicines to promote higher quality weight loss and enhance overall metabolic health and function, as well as a pipeline of therapeutic candidates in immuno-oncology for some of the most-difficult-to-treat cancers, including solid tumors in lung, colorectal, and breast cancer, head and neck cancer, pancreatic cancer and glioblastoma, a fast-growing brain tumor. Dr. Brenner has a strong history of success heading drug discovery and development teams at several of the world's leading pharmaceutical companies, including AstraZeneca, Eli Lilly and Company, Pfizer Inc., and Merck Research Laboratories. Most recently, Dr. Brenner served as the CSO at Pfenex Inc., which, using its patented Pfēnex Expression Technology® platform, created an advanced pipeline of therapeutic equivalents, vaccines, biologics and biosimilars. Pfenex was acquired by Ligand Pharmaceuticals Incorporated for approximately $516 million in October 2020. Previously, Dr. Brenner served as the CSO at Recursion Pharmaceuticals, Inc., a company focused on accelerating drug discovery for rare diseases and diseases with high unmet medical need. Prior to his time at Recursion, Dr. Brenner was Vice President and Head of Research & Early Development at Stoke Therapeutics, Inc., a biotechnology company using antisense oligonucleotides to increase gene expression for the treatment of rare diseases. Prior to Stoke, Dr. Brenner was Executive Director at Merck, where he built a biotech unit from scratch, focusing his team's research on diabetes and nonalcoholic steatohepatitis (NASH). Earlier in his career, Dr. Brenner was the Senior Director and Head of cardiovascular, renal, and metabolism (CVRM) biosciences at AstraZeneca. In addition, Dr. Brenner was an Associate Research Fellow at Pfizer where he led the islet biology and in vivo pharmacology in the CVMED Target Exploration Unit before assuming the role of Head of the Insulin Resistance Group.Dr. Brenner has a DVM, Veterinary Medicine, Ludwig-Maximilians-Universität München and a Ph.D., Pharmacology  Tieraerztliche Hochschule Hannover.#MartinBrenner #iBio #Cardiometabolic #Obesity #Medicines #WeightLoss #MetabolicHealth #ImmunoOncology #GLP1 #BispecificAntibodies #ArtificialIntelligence #TransformingGrowthFactorBeta #Myostatin #ActivinA #ActivinE #MuscleMass #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #ViralPodcast #STEM #Innovation #Technology #Science #ResearchSupport the show

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/MRT865. CME/MOC/NCPD/AAPA/IPCE credit will be available until March 30, 2026.Navigating the ADC Roadmap for Modern Gynecologic Cancer Treatment: Expert Perspectives on Personalizing Patient Care In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Foundation for Women's Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AbbVie, and Pfizer Inc. and Genmab.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/MRT865. CME/MOC/NCPD/AAPA/IPCE credit will be available until March 30, 2026.Navigating the ADC Roadmap for Modern Gynecologic Cancer Treatment: Expert Perspectives on Personalizing Patient Care In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Foundation for Women's Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AbbVie, and Pfizer Inc. and Genmab.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/MRT865. CME/MOC/NCPD/AAPA/IPCE credit will be available until March 30, 2026.Navigating the ADC Roadmap for Modern Gynecologic Cancer Treatment: Expert Perspectives on Personalizing Patient Care In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Foundation for Women's Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AbbVie, and Pfizer Inc. and Genmab.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/MRT865. CME/MOC/NCPD/AAPA/IPCE credit will be available until March 30, 2026.Navigating the ADC Roadmap for Modern Gynecologic Cancer Treatment: Expert Perspectives on Personalizing Patient Care In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Foundation for Women's Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AbbVie, and Pfizer Inc. and Genmab.Disclosure information is available at the beginning of the video presentation.

This episode covers: Cardiology This Week: A concise summary of recent studies AI and the future of the Electrocardiogram The heart in rheumatic disorders and autoimmune diseases Statistics Made Easy: Bayesian analysis Host: Susanna Price Guests: Carlos Aguiar, Paul Friedman, Maya Buch  Want to watch that episode? Go to: https://esc365.escardio.org/event/1801 Disclaimer: ESC TV Today is supported by Bristol Myers Squibb. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsor. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. Declarations of interests: Stephan Achenbach, Antonio Greco, Nicolle Kraenkel and Susanna Price have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Novo Nordisk, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Maya Buch has declared to have potential conflicts of interest to report: grant/research support paid to University of Manchester from Gilead and Galapagos; consultant and/or speaker with funds paid to University of Manchester for AbbVie, Boehringer Ingelheim, CESAS Medical, Eli Lilly, Galapagos, Gilead Sciences, Medistream and Pfizer Inc; member of the Speakers' Bureau for AbbVie with funds paid to University of Manchester. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Paul Friedman has declared to have potential conflicts of interest to report: co-inventor of AI ECG algorithms. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Host: Susanna Price Guest: Maya Buch Want to watch that extended interview? Go to: https://esc365.escardio.org/event/1801?resource=interview Disclaimer: ESC TV Today is supported by Bristol Myers Squibb. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsor. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. Declarations of interests: Stephan Achenbach, Nicolle Kraenkel and Susanna Price have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Novo Nordisk, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Maya Buch has declared to have potential conflicts of interest to report: grant/research support paid to University of Manchester from Gilead and Galapagos; consultant and/or speaker with funds paid to University of Manchester for AbbVie, Boehringer Ingelheim, CESAS Medical, Eli Lilly, Galapagos, Gilead Sciences, Medistream and Pfizer Inc; member of the Speakers' Bureau for AbbVie with funds paid to University of Manchester. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

uniQure Biopharma B.V. v. Pfizer Inc.

In this podcast Simon Taylor (Pharmaron UK) interviews Kevin Beaumont, a highly experienced DMPK scientist, leader and drug developer who has lived and breathed the role of the DMPK Project Representative throughout his 40-year industrial career.  With experience of delivering clinical drug candidates across multiple therapeutic areas with two major pharma companies (Pfizer and AstraZeneca) Kevin describes his entry into the role, the value of people, in roles as mentee and mentor, and the shift in emphasis of DMPK from a discipline supporting drug development to one driving drug discovery.  Covering key concepts related to project DMPK and minimising drug attrition this is a wide-ranging discussion with real life examples spanning discovery to clinical. The episode explores the following: The key role of the DMPK Project Representative and required knowledge Important concepts that have shaped DMPK drug design such as Physicochemical and application to drug design Free drug theory Human PK prediction, value and uncertainties Modalities  The role of DMPK in reducing drug failure in the clinic  Key individuals that have shaped DMPK science and Kevin's career The future of the DMPK Project Representative and the next generation  Speaker:Kevin Beaumont – Senior Director DMPK, Oncology R&D, AstraZeneca Kevin has worked in the pharmaceutical industry for over 40 years in the fields of drug metabolism and pharmacokinetics, especially as it relates to drug discovery support. His major area of expertise is in the modulation of physicochemistry to affect drug disposition and in prediction of human pharmacokinetics from preclinical information. He is the author of over 50 peer reviewed publications.  Kevin joined the Department of Drug Metabolism at Pfizer Sandwich UK in 1983, directly from his BSC in Biochemistry at the University of London.  Under the mentorship of Dr Dennis Smith Kevin's early career involved developing a fundamental understanding of the basics of DMPK support to discovery and development projects. This included developing expertise in small molecule bioanalysis, completion of radiolabelled ADME studies and direct DMPK support to discovery and development projects.  In 2011, Kevin transferred to Pfizer Inc in Boston Massachusetts, where he was responsible for DMPK/ADME support to the Cardiovascular, Inflammation and Immunology and Rare Disease Therapeutic Areas.  In 2020 Kevin returned to the UK and is currently with AstraZeneca supporting Oncology R&D with DMPK expertise including modalities beyond small molecules. Stay tuned for more podcasts in our Pharmaron DMPK Insights Series!

Guillain-Barré syndrome (GBS) is a rare disorder that causes muscle weakness and sometimes paralysis. It's caused by the body's immune system damaging nerves. While most cases are triggered by respiratory or gastrointestinal infections, vaccinations have also been linked to GBS pathogenesis. GBS can last from weeks to years, but most people start to recover within a few weeks. The earlier symptoms improve, the better the outlook. Physical therapy is important to prevent muscle contractures and deformities. Some people may experience long-term weakness, numbness, fatigue, or pain. A small percentage of people with GBS may have a relapse, which can cause muscle weakness years after symptoms end. On Jan 7, 2025, the FDA required and approved UPDATED safety labeling changes to the Prescribing Information for Abrysvo (Respiratory Syncytial Virus Vaccine) manufactured by Pfizer Inc. and Arexvy (Respiratory Syncytial Virus Vaccine, Adjuvanted) manufactured by GlaxoSmithKline Biologicals. Specifically, FDA has required each manufacturer to include a new warning about the risk for Guillain-Barré syndrome (GBS) following administration of their Respiratory Syncytial Virus (RSV) vaccine. Who is most at risk for GBS? Where pregnant women affected? This is important information….listen in for details.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete NCPD/ILNA information, and to apply for credit, please visit us at PeerView.com/XRZ865. NCPD/ILNA credit will be available until December 30, 2025.Personalized Care and Tailored Treatment Plans for Gynecologic Cancers: Practical Nurse Guidance on Utilizing Modern Therapeutic Approaches In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, Foundation for Women's Cancer, and National Ovarian Cancer Coalition. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AbbVie, AstraZeneca, Daiichi Sankyo, and Pfizer Inc. and Genmab.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete NCPD/ILNA information, and to apply for credit, please visit us at PeerView.com/XRZ865. NCPD/ILNA credit will be available until December 30, 2025.Personalized Care and Tailored Treatment Plans for Gynecologic Cancers: Practical Nurse Guidance on Utilizing Modern Therapeutic Approaches In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, Foundation for Women's Cancer, and National Ovarian Cancer Coalition. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AbbVie, AstraZeneca, Daiichi Sankyo, and Pfizer Inc. and Genmab.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete NCPD/ILNA information, and to apply for credit, please visit us at PeerView.com/XRZ865. NCPD/ILNA credit will be available until December 30, 2025.Personalized Care and Tailored Treatment Plans for Gynecologic Cancers: Practical Nurse Guidance on Utilizing Modern Therapeutic Approaches In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, Foundation for Women's Cancer, and National Ovarian Cancer Coalition. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AbbVie, AstraZeneca, Daiichi Sankyo, and Pfizer Inc. and Genmab.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete NCPD/ILNA information, and to apply for credit, please visit us at PeerView.com/XRZ865. NCPD/ILNA credit will be available until December 30, 2025.Personalized Care and Tailored Treatment Plans for Gynecologic Cancers: Practical Nurse Guidance on Utilizing Modern Therapeutic Approaches In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, Foundation for Women's Cancer, and National Ovarian Cancer Coalition. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AbbVie, AstraZeneca, Daiichi Sankyo, and Pfizer Inc. and Genmab.Disclosure information is available at the beginning of the video presentation.

Send us a textWelcome to this week's Safe Dividend Investing's podcast. For greater accuracy,  you may want to go to the printed transcript provided with this podcast for the list of 5 outstanding US stocks and 5 outstanding Canadian stocks identified this week. It is interesting to see how scoring these 10 stocks revealed their hidden strengths and weaknesses that were not initially evident.The first 190 Safe Dividend Investing podcasts answered questions from listeners and readers of my publications. Not wanting to repeat the same material that had already been covered, the weekly podcasts now deal with identifying interesting stocks whose growth in the last week may make them worth considering as possible portfolio acquisitions.Visit www.informus.ca for information on my six investment guide books and stock scoring software.IANimacd@informus.caIan Duncan MacDonaldAuthor, Artist, Commercial Risk Consultant,President of Informus Inc 2 Vista Humber Drive Toronto, Ontario Canada, M9P 3R7 Toronto Telephone - 416-245-4994 New York Telephone - 929-800-2397 imacd@informus.ca

This Day in Legal History: New York Grants Women Right to VoteOn November 6, 1917, New York became one of the first eastern states to grant women the right to vote, a pivotal victory for the suffrage movement in the United States. The state's voters approved a constitutional amendment that extended suffrage to women, marking a significant shift in public opinion and advancing the national push for equal voting rights. New York was the most populous state to enact such a measure, lending critical momentum to the cause and demonstrating that widespread support for women's suffrage was achievable in even the largest urban areas.This victory was the result of decades of persistent activism and organizing by leaders such as Carrie Chapman Catt, who spearheaded the Empire State Campaign Committee, and countless local suffragists who canvassed tirelessly for public support. Women in New York had actively campaigned, held rallies, and built coalitions, especially focusing on mobilizing working-class women and men. The successful vote was seen as a clear mandate for gender equality and significantly influenced other states and Congress.New York's decision to enfranchise women not only energized the movement but also helped propel the passage of the 19th Amendment to the U.S. Constitution in 1920, which granted voting rights to women nationwide. This milestone in New York underscored the growing acknowledgment of women's role in public and political life, laying groundwork for further social and political reforms across the country.The U.S. Supreme Court recently heard arguments in a case concerning whether a heightened standard of proof is necessary for employers claiming that workers are exempt from overtime pay under the Fair Labor Standards Act (FLSA). Currently, there is a split among federal circuits on this issue, with the Fourth Circuit requiring a "clear and convincing" evidence standard, while other circuits apply the lower "preponderance of the evidence" standard, which means the employer must show it is more likely than not that an exemption applies. The case has significant implications for both workers' rights and business costs.Representing E.M.D. Sales, attorney Lisa Blatt argued that the default civil standard, preponderance of the evidence, should apply to FLSA cases, as imposing a stricter standard would burden employers and potentially lead to layoffs. Conversely, Lauren Bateman, representing employees and supported by Public Citizen, contended that because FLSA regulations protect critical worker health, safety, and economic welfare, a higher standard is warranted to ensure these protections are meaningful.Justice Ketanji Brown Jackson underscored that the FLSA aims not only to provide fair pay but also to ensure a safe workplace and expand employment, suggesting the importance of potentially adopting a stricter standard. Meanwhile, Justice Clarence Thomas raised questions about why the FLSA should receive special treatment over other laws that also protect essential rights, such as those addressing discrimination.The case attracted varied views on the potential broader impacts of raising the standard of proof. Some justices, like Samuel Alito, questioned how the court would measure the relative importance of rights across federal laws. The Justice Department, represented by Aimee Brown, supported the employer's position, noting that Congress enacts many laws with public benefits, yet courts rarely apply a heightened standard of proof in such cases.The Supreme Court's eventual decision could standardize how proof requirements are applied in overtime cases and influence both worker protections and business practices across the country.US Supreme Court Leans Toward Business in Overtime Dispute (1)A new lawsuit accuses Pfizer Inc. of failing to warn patients that its contraceptive injection, Depo-Provera, could increase the risk of brain tumors. Plaintiff Taylor Devorak filed the complaint in California, alleging that Pfizer and other manufacturers had a duty to research and disclose potential links between Depo-Provera, as well as similar progesterone-based drugs, and intracranial meningiomas, a type of brain tumor. The lawsuit seeks damages based on claims of failure to warn, defective design, negligence, and misrepresentation.Devorak's case follows similar lawsuits filed recently in California and Indiana. Her complaint notes that although the drug has been FDA-approved for over 30 years and widely used, Pfizer has not updated the U.S. labeling to reflect these risks, even as health authorities in the EU and UK now include warnings about meningioma for such medications. A 2024 study published in the *British Medical Journal* found a substantial increase in risk for brain tumors with prolonged use of medroxyprogesterone acetate, the active ingredient in Depo-Provera.In response, Pfizer asserts that Depo-Provera has been a safe option for millions and plans to “vigorously defend” against the claims. The case has brought renewed attention to safety and disclosure practices in the pharmaceutical industry, particularly around long-established medications.Pfizer Accused of Hiding Contraceptive's Brain Tumor Link (1)Following Donald Trump's recent election as U.S. president, the criminal cases against him are likely to be halted for the duration of his term. Trump, the first former president to face criminal charges, had four active prosecutions, including charges related to attempts to overturn the 2020 election results, a hush-money payment linked to Stormy Daniels, and unlawful retention of classified documents. Trump, who has pleaded not guilty to all charges and dismissed the cases as politically motivated, has stated he would immediately dismiss Special Counsel Jack Smith, responsible for the federal prosecutions on election interference and document retention.While Trump can halt federal cases, he has less control over state cases, such as the New York hush-money and Georgia election interference cases. However, his presidency could still effectively delay or complicate these proceedings. Legal experts expect delays in his New York sentencing, which had already been postponed, citing potential presidential immunity arguments.In Georgia, Trump's lawyers are working to pause proceedings under the argument that a sitting president should not face criminal prosecution. Additionally, his team has challenged Fulton County District Attorney Fani Willis's involvement, aiming to disqualify her based on alleged misconduct. Ultimately, experts believe Trump's presidency will prevent the state-level cases from moving forward until his term concludes.Trump's impending return to White House brings criminal cases to a halt | ReutersThe U.S. Supreme Court will hear arguments on Facebook's effort to dismiss a securities fraud lawsuit brought by shareholders who claim the company misled investors about the misuse of user data. The lawsuit, initiated by Amalgamated Bank in 2018, argues that Facebook violated the Securities Exchange Act by failing to disclose the 2015 Cambridge Analytica data breach, which affected over 30 million users and contributed to Donald Trump's 2016 presidential campaign. Shareholders allege that Facebook presented data privacy risks as hypothetical even though the breach had already occurred.Facebook contends that it was not legally required to disclose the prior breach and that reasonable investors would interpret risk disclosures as forward-looking. A federal judge initially dismissed the case, but the Ninth Circuit Court revived it, noting that Facebook's statements misrepresented an already-realized risk. The Supreme Court's decision, expected by June, could influence the standards for securities fraud cases, making it harder for private parties to pursue claims. This case, along with a similar appeal by Nvidia, could further limit the liability of companies for nondisclosure of past risks. Past Cambridge Analytica fallout has led Facebook to settle related SEC and FTC actions, paying $100 million and $5 billion, respectively.US Supreme Court to hear Facebook bid to escape securities fraud suit | Reuters This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.minimumcomp.com/subscribe

This EAU podcast has been developed with financial support from Pfizer Inc for healthcare professionals based in the EU and UK. The content discussed here was up to date at the time of recording in June 2024 and may not be suitable in your local market. The EAU has retained full editorial control.In this episode, the panel chair of the EAU guidelines on prostate cancer, Prof. Philip Cornford (GB) is at UROonco24 in Budapest, and talks to medical oncologist Dr. Ursula Vogl (CH) on the role of genetic testing for prostate cancer.Dr. Vogl discusses why genetic testing is important, and defines both somatic (tissue) testing, and germline testing. She shares her opinion on why ideally both should be done, and when, as well as an explanation of the guidelines.To keep updated on prostate cancer developments, go to the UROONCO Prostate Cancer Educational Platform. For more EAU podcasts, please go to your favourite podcast app and subscribe to our podcast channel for regular updates: Apple Podcasts, Spotify, EAU YouTube channel.PP-UNP-GBR-10244.  September 2024 

Dive into this episode of Biotech 2050 where host Rahul Chaturvedi interviews Jeb Keiper, CEO of Nimbus Therapeutics. Discover Jeb's fascinating journey from MIT chemist to industry leader, as he shares insights into Nimbus' groundbreaking work in ultra-rare diseases, innovative corporate structure, and strategic capital management. Emphasizing bold risks, team collaboration, and strategic partnerships, Jeb shares valuable insights into biotech's challenges, opportunities, and the future of cancer therapies. Biography: Jeb Keiper, M.S., M.B.A., has served as our President and Chief Executive Officer and as a member of our board of directors since October 2018. He previously served as Chief Business Officer from November 2014 to October 2018 and as Chief Financial Officer from February 2017 to October 2018. Since joining Nimbus, Mr. Keiper has overseen the discovery and development of three programs into clinical testing across a range of indications, over $400M raised in equity funding, executed deals worth over $7B, and the return of over $4B in gains back to equity holders. Prior to joining Nimbus, Mr. Keiper served as the Vice President of Business Development at GSK Oncology (a subsidiary of GlaxoSmithKline plc (NYSE: GSK)) from March 2011 to October 2014, where he was responsible for identifying and concluding several critical collaborations for GSK in Oncology, including the Novartis-GSK Oncology integration, and spent a decade at GSK in various business development leadership roles. Prior to GSK, Mr. Keiper was a consultant at McKinsey & Company starting in September 2000-2002, then September 2004 to 2005, after having started his career as a pharmaceutical chemist at Pfizer Inc. (NYSE: PFE) in 1998. Mr. Keiper currently serves as a member of the board of directors at private biotechnology companies Cardurion Pharmaceuticals, Inc., and ROME Therapeutics, Inc. Mr. Keiper received two B.S. degrees, one in Chemistry and one in Chemical Engineering, as well as an M.S. in Chemical Engineering from the Massachusetts Institute of Technology, and an M.B.A. from the MIT Sloan School of Management with joint program in Biomedical Enterprises with the Harvard Medical School.

Edward O'Keefe, author of “The Loves of Theodore Roosevelt,” joins Margaret Hoover to discuss the “extraordinary and unsung” women who shaped the life and legend of the 26th president–and why his legacy still resonates today. O'Keefe, a former journalist and North Dakota native who is now CEO of the Theodore Roosevelt Presidential Library Foundation, details Roosevelt's relationships with his mother, his sisters, and his wives and how they contributed to his successes. He comments on Roosevelt's appeal to politicians in both parties today, his expansive use of executive power, and his support for gender equality. He also discusses the role of First Lady Edith Roosevelt in creating the modern White House. O'Keefe reflects on what Roosevelt's experience as a vice president who rose to the Oval Office after an assassination reveals about the importance of presidential running mates and whether North Dakota Governor Doug Burgum would be a good choice for Donald Trump. He also addresses Roosevelt's record on race and how the library intends to handle a controversial statue depicting the president on horseback flanked by a Native American and a Black man that was removed from outside the American Museum of Natural History in 2022. Support for “Firing Line for Margaret Hoover” is provided by Robert Granieri, Vanessa and Henry Cornell, The Emmet Family Charitable Foundation, The Fairweather Foundation, The Tepper Foundation, Peter and Mary Kalikow, The Asness Family Foundation, The Beth and Ravenel Curry Foundation, Kathleen and Andrew McKenna through The McKenna Family Foundation, Charles R. Schwab, The Eric and Wendy Schmidt Fund for Strategic Innovation, Pritzker Military Foundation on behalf of the Pritzker Military Museum and Library, The Rosalind P. Walter Foundation, Damon Button, Craig Newmark Philanthropies, The Marc Haas Foundation, Roger and Susan Hertog, Cheryl Cohen Effron and Blair Effron, and Al and Kathy Hubbard. Corporate funding is provided by Stephens Inc. and Pfizer Inc.

CardioNerds Co-Founder Dr. Daniel Ambinder, Series Co-Chair Dr. Giselle Suero Abreu (FIT at MGH), and Episode Lead Dr. Iva Minga (FIT at the University of Chicago) discuss the use of multi-modality cardiovascular imaging in cardio-oncology with expert faculty Dr. Nausheen Akhter (Northwestern University). Show notes were drafted by Dr. Sukriti Banthiya and episode audio was edited by CardioNerds Intern and student Dr. Diane Masket. They use illustrative cases to discuss: Recommendations on the use of multimodality imaging, including advanced echocardiographic techniques and cardiac MRI, in patients receiving cardiotoxic therapies and long-term surveillance. Role of nuclear imaging (MUGA scan) in monitoring left ventricular ejection fraction. Use of computed tomography to identify and/or monitor coronary disease. Imaging diagnosis of cardiac amyloidosis. This episode is supported by a grant from Pfizer Inc. This CardioNerds Cardio-Oncology series is a multi-institutional collaboration made possible by contributions of stellar fellow leads and expert faculty from several programs, led by series co-chairs, Dr. Giselle Suero Abreu, Dr. Dinu Balanescu, and Dr. Teodora Donisan.  CardioNerds Cardio-Oncology PageCardioNerds Episode PageCardioNerds AcademyCardionerds Healy Honor Roll CardioNerds Journal ClubSubscribe to The Heartbeat Newsletter!Check out CardioNerds SWAG!Become a CardioNerds Patron! References -  Multi-modality Imaging in Cardio-Oncology Baldassarre L, Ganatra S, Lopez-Mattei J, et al. Advances in Multimodality Imaging in Cardio-Oncology. J Am Coll Cardiol. 2022 Oct, 80 (16) 1560–1578.

Democratic Rep. Ritchie Torres of the Bronx sits down with Margaret Hoover to talk about Israel, immigration, and other issues that impact voters of color as polls suggest support for Donald Trump is rising among traditionally Democratic voting blocs that will play a pivotal role in the 2024 election. Torres, the first openly gay Afro-Latino member of Congress, discusses how growing up in public housing with a single mother influences his perspective and his policy positions. After Trump's rally in his district, Torres assesses Trump's potential to make gains with Black and Hispanic voters and what President Biden can do to regain their support. He comments on Biden's executive orders on immigration and the failure of Congress to address the border crisis. Torres, who is one of Israel's most vocal supporters in the House, explains why he became a Zionist, defends Biden's record on Israel, and reflects on how the progressive movement has become radicalized on this and other issues over the last decade.  Support for “Firing Line for Margaret Hoover” is provided by Robert Granieri, Vanessa and Henry Cornell, The Emmet Family Charitable Foundation, The Fairweather Foundation, The Tepper Foundation, Peter and Mary Kalikow, The Asness Family Foundation, The Beth and Ravenel Curry Foundation, Kathleen and Andrew McKenna through The McKenna Family Foundation, Charles R. Schwab, The Eric and Wendy Schmidt Fund for Strategic Innovation, Pritzker Military Foundation on behalf of the Pritzker Military Museum and Library, The Rosalind P. Walter Foundation, Damon Button, Craig Newmark Philanthropies, The Marc Haas Foundation, Roger and Susan Hertog, Cheryl Cohen Effron and Blair Effron, and Al and Kathy Hubbard. Corporate funding is provided by Stephens Inc. and Pfizer Inc.

Following a U.N. report accusing Israel of war crimes, Margaret Hoover sits down with Dan Senor, a former foreign policy aide to Mitt Romney and the host of the podcast “Call Me Back,” to the daring rescue of four Israeli hostages in Gaza, prospects for a cease-fire, and the new U.N. report accusing both Hamas and Israel of war crimes. Senor defends how Israel has conducted the war, arguing that while civilian deaths are inevitable in any conflict, the Israel Defense Forces have done all they can to protect innocent lives in Gaza. He says that while individual Israeli soldiers may have done “stupid things,” Israel is “fighting war” that was inflicted upon it by Hamas. Senor also notes that Hamas hides its fighters amid Palestinian civilians in an effort to maximize the suffering inflicted on the people of Gaza — an attempt, he says, to put Israel in an “impossible position” and make the Jewish State an international pariah.  Senor is the author of “The Genius of Israel,” a book that looks at the resilience of Israeli society despite its internal conflicts and the numerous wars it has fought with neighboring states and terrorist groups. An outspoken defender of Israel, Senor discusses whether it's just a matter of time before the IDF is sent to fight Hezbollah, the powerful Lebanon-based militant group backed by Iran. He also discusses why Israeli Prime Minister Benjamin Netanyahu has been reluctant to discuss postwar plans for Gaza, and whether criticism of Israel's war effort is driven primarily by antisemitism.  Support for “Firing Line for Margaret Hoover” is provided by Robert Granieri, Vanessa and Henry Cornell, The Fairweather Foundation, The Tepper Foundation, Peter and Mary Kalikow, The Asness Family Foundation, The Beth and Ravenel Curry Foundation, Kathleen and Andrew McKenna through The McKenna Family Foundation, Charles R. Schwab, The Eric and Wendy Schmidt Fund for Strategic Innovation, Pritzker Military Foundation on behalf of the Pritzker Military Museum and Library, The Rosalind P. Walter Foundation, Damon Button, Craig Newmark Philanthropies, The Marc Haas Foundation, Roger and Susan Hertog, Cheryl Cohen Effron and Blair Effron, and Al and Kathy Hubbard. Corporate funding is provided by Stephens Inc. and Pfizer Inc.

As the end of Donald Trump's first trial nears, Margaret Hoover sits down with conservative attorney and former Trump supporter George Conway to discuss the case and the prospect of another Trump presidency. Conway defends the Manhattan prosecution, talks about watching Trump in the courtroom, and explains why he disagrees with those who say the case is driven by politics. He also argues Trump has received preferential treatment from the courts, including in the classified documents case overseen by Judge Aileen Cannon, who he says is “corrupt” and “not competent.” Conway, whose ex-wife Kellyanne managed Trump's 2016 campaign, explains why he sees a second Trump term as a threat to American democracy and why he now believes Trump is a narcissistic sociopath who is unfit for public office. Conway, a longtime member of the Federalist Society, assesses whether Trump's Supreme Court nominations were worth the damage he has done and why conservative institutions have failed to respond to his abuses of power. He also addresses reports of an upside-down American flag seen at Justice Samuel Alito's home in January 2021. Conway reflects on his own political evolution from a key player in Bill Clinton's impeachment to big-dollar donor to Joe Biden's reelection campaign. He contrasts Clinton and Trump, and he explains why he teared up when he cast a vote for Biden in 2020. Support for “Firing Line for Margaret Hoover” is provided by Robert Granieri, Vanessa and Henry Cornell, The Fairweather Foundation, The Tepper Foundation, Peter and Mary Kalikow, The Asness Family Foundation, The Beth and Ravenel Curry Foundation, Kathleen and Andrew McKenna through The McKenna Family Foundation, Charles R. Schwab, The Eric and Wendy Schmidt Fund for Strategic Innovation, Pritzker Military Foundation on behalf of the Pritzker Military Museum and Library, The Rosalind P. Walter Foundation, Damon Button, Craig Newmark Philanthropies, The Marc Haas Foundation, Roger and Susan Hertog, Cheryl Cohen Effron and Blair Effron, and Al and Kathy Hubbard. Corporate funding is provided by Stephens Inc. and Pfizer Inc.

Historian Doris Kearns Goodwin sits down with Margaret Hoover to discuss “An Unfinished Love Story,” her new book recounting the 1960s from her perspective and that of her late husband, presidential speechwriter Dick Goodwin. The Pulitzer Prize-winning biographer recalls the genesis of the project and reflects on the difference between writing about her husband and long-dead presidents like Abraham Lincoln and Franklin Roosevelt. She details Dick Goodwin's work for John F. Kennedy and Lyndon Johnson, including writing Johnson's address to Congress after the Bloody Sunday march in Selma. Goodwin also addresses declining trust in government since Johnson's presidency, which she traces to his handling of the Vietnam War. She discusses her husband's later work on Al Gore's 2000 concession speech and how presidential candidates recognized the importance of putting patriotism before partisanship after close elections prior to 2020.  Goodwin considers parallels between the 1850s and today and the prospect that current divisions will lead to another civil war. She also explains why she sees her own love story with America as unfinished and why she believes the country has a long way to go to live up to its ideals. Support for “Firing Line for Margaret Hoover” is provided by Robert Granieri, Vanessa and Henry Cornell, The Fairweather Foundation, The Tepper Foundation, Peter and Mary Kalikow, The Asness Family Foundation, The Beth and Ravenel Curry Foundation, Kathleen and Andrew McKenna through The McKenna Family Foundation, Charles R. Schwab, The Eric and Wendy Schmidt Fund for Strategic Innovation, Pritzker Military Foundation on behalf of the Pritzker Military Museum and Library, The Rosalind P. Walter Foundation, Damon Button, Craig Newmark Philanthropies, The Marc Haas Foundation, Roger and Susan Hertog, Cheryl Cohen Effron and Blair Effron, and Al and Kathy Hubbard. Corporate funding is provided by Stephens Inc. and Pfizer Inc.

Sara Madsen Miller shares her journey from pursuing a business degree to working at Pfizer and eventually becoming the COO of 1820 Productions. She highlights the importance of mentorship and the role it played in her early years. Sara also discusses the challenges she faced leading a team of men and the strategies she used to navigate that space. She emphasizes the significance of creating a strong company culture and how it contributes to the success of 1820 Productions. In this conversation, Sara Madsen Miller, Chief Operating Officer and Executive Producer for 1820 Productions, an Emmy award-winning production company, discusses the unique and encouraging environment her company creates for its clients and employees. She emphasizes the importance of providing opportunities for women and diversity in the television and film industry. Sara also highlights the value of kindness, understanding, and feedback in the workplace, drawing from her own experiences and mentorship. She shares lessons from her mentors and the significance of building a positive reputation. Sara encourages the next generation to promote themselves, seek leadership opportunities, and learn about artificial intelligence. She finds inspiration in work ethic, great stories, and continuous learning. 1820 creatively and strategically helps businesses drive market share and brand awareness by developing visual content to uniquely fit every need. Sara has developed and executive produced hit television shows, compelling documentaries, and prize-winning commercials. Through 1820, she has partnered with large clients like Frito-Lay, Toyota and Mastercard, collaborated with advertising agencies such as GSP, Edelman and The Richards Group as well as created programming content for television networks including ABC, BET and DISCOVERY. 1820's expertise has helped clients win multiple Emmy Awards and Gold Addy Awards. Prior to joining 1820 Productions, Madsen Miller had 14 years of executive leadership with Pfizer Inc. managing portfolios of over $750 million. As a result of her keen management, strategic business approach and communication skills, Sara won numerous leadership and sales awards including the Vice President's Management Club for the top 10% of managers. She received both a degree in Journalism and Mass Communication as well as Business and Public Administration Degree from Drake University and Executive Education from Dartmouth College's Tuck School of Business. Sara's service in the community includes Board Member Dallas Regional Chamber, Board Member AT&T Performing Arts Center Endowment Board, Board Member Housing Forward and Advisory Council for the TWU Jane Nelson Institute for Women's Leadership. She's been honored with a number of civic awards including the Dallas Business Journal Women in Business Award and the American Advertising Federation's Shining Star Award. Madsen Miller lives in Dallas with her husband and best dog ever Zoë. Book Recommendations: Nice Girls Don't Get the Corner Office, Lois Frankel What Color is My Parachute?, Richard Bolles Unreasonable Hospitality: The Remarkable Power of Giving People More than They Expect, Will Guidara How to Tell a Story: The Essential Guide to Memorable Storytelling from The Moth, Meg Bowles Contact Sara: Website/Social info: LinkedIn: https://www.linkedin.com/in/sara-madsen-miller-8746586/ Instagram: @sara.madsenmiller Company Website:  https://1820productions.com/

CardioNerds Co-Founder Dr. Daniel Ambinder, Episode Chair Dr. Dinu Balanescu, and FIT Lead Dr. Natalie Tapaskar discuss advanced heart failure in CardioOncology with expert Dr. Richard Cheng. Audio editing by CardioNerds Academy Intern, Dr. Akiva Rosenzveig. In this episode, we discuss the spectrum of advanced heart failure in patients with a history of cancer. We dissect cancer therapy-related cardiac dysfunction (CTRCD) cases and the imaging and biomarker tools available for risk stratification and disease monitoring. We delve into the data on the use of guideline-directed medical therapy (GDMT) and cardiac resynchronization therapy (CRT) in these patients. We discuss the risk of prior radiation and chemotherapy during cardiac surgery. Finally, we learn about the post-transplant risk of rejection, recurrent malignancy, and de-novo malignancies, as well as treatment strategies we can employ for these patients. This episode is supported by a grant from Pfizer Inc. This CardioNerds Cardio-Oncology series is a multi-institutional collaboration made possible by contributions of stellar fellow leads and expert faculty from several programs, led by series co-chairs, Dr. Giselle Suero Abreu, Dr. Dinu Balanescu, and Dr. Teodora Donisan.  CardioNerds Cardio-Oncology PageCardioNerds Episode PageCardioNerds AcademyCardionerds Healy Honor Roll CardioNerds Journal ClubSubscribe to The Heartbeat Newsletter!Check out CardioNerds SWAG!Become a CardioNerds Patron! Pearls and Quotes - Advanced Heart Failure in CardioOncology Use the HFA-ICOS risk tool to understand the baseline risk of developing cancer therapy-related cardiac dysfunction (CTRCD). Key factors are type of cancer therapy, baseline CV risk factors, and age. A relative change in global longitudinal strain of more than 15% from baseline is a marker of early cardiac dysfunction and predicts the subsequent risk for systolic dysfunction in patients undergoing cardiotoxic chemotherapy. Statins may be useful in prevention of cardiovascular dysfunction in patients receiving anthracycline chemotherapy. There is limited data on the 4 pillars of GDMT in prevention of CTRCD, but should be started early once CRTCD is suspected or diagnosed! Mediastinal radiation causes adhesions and scarring which increase the risk of bleeding during cardiac surgery, lead to longer operative times, and can lead to RV failure and poor wound healing. Patients with a pre-transplant history of malignancy have a higher risk of mortality due to post-transplant malignancy. And patients with active cancer should not be considered for heart transplant. Post-transplant malignancy risk can be mitigated by utilizing an mTOR based, CNI free immunosuppression regimen. Show notes - Advanced Heart Failure in CardioOncology How do cardio-oncology and advanced heart failure intersect? There are 3 basic populations of patients to consider:Patients with advanced heart failure who develop cancer.Patients with pre-existing chemotherapy and radiation exposure for cancer treatment who later develop advanced heart failureHeart transplant recipients who, in the long term are at very high risk of developing cancer Cardio-oncologists must consider risk assessment and mitigation, long-term prognosis, and treatment strategies for each of these unique populations. How can we assess the risk of developing cardiovascular disease during cancer treatment (CTRCD)? There are many proposed risk tools. However, the majority are not well-validated. One of the most used tools is the HFA-ICOS risk tool.1You can select the planned cancer therapy for the patient (anthracyclines, HER-2, VEGF, RAF/MEK inhibitors, Kinase inhibitors, multiple myeloma therapies) and then calculate their risk of developing CV disease during cancer treatment based on baseline variables:1) previous history of CV disease,2) biomarkers – troponin and NT-proBNP3)age,4) CV risk factors -HTN, DM,

Author and journalist Fareed Zakaria joins Margaret Hoover to talk about his recent book, “Age of Revolutions,” and how past periods of progress and backlash inform our present revolutionary moment. Zakaria, host of CNN's “Fareed Zakaria GPS,” reflects on a full-blown cultural backlash against decades of social and political change that has fueled the rise of Donald Trump. He also discusses the next industrial revolution driven by artificial intelligence and the progress and disruption it may cause. Zakaria comments on the challenge President Biden faces addressing the crisis at the southern border. He also addresses campus protests over Israel's actions in Gaza and what he sees as the failure of Biden's efforts to influence Israeli policy. Assessing America's place in a changing world, Zakaria makes an argument for aggressive U.S. support for Ukraine and voices concern about the impact of emerging Republican isolationism in a second Trump presidency. He discusses the race between Trump and Biden, the prospect of a historic political realignment, and the parallels between 1968 and 2024. (NOTE: This interview was recorded on May 1, prior to the announcement that the U.S. has put arms shipments to Israel on hold out of concern that American weapons would be used in an assault on the city of Rafah.) Support for “Firing Line for Margaret Hoover” is provided by Robert Granieri, Vanessa and Henry Cornell, The Fairweather Foundation, The Tepper Foundation, Peter and Mary Kalikow, The Asness Family Foundation, The Beth and Ravenel Curry Foundation, Kathleen and Andrew McKenna through The McKenna Family Foundation, Charles R. Schwab, The Eric and Wendy Schmidt Fund for Strategic Innovation, Pritzker Military Foundation on behalf of the Pritzker Military Museum and Library, The Rosalind P. Walter Foundation, Damon Button, Craig Newmark Philanthropies, The Marc Haas Foundation, Roger and Susan Hertog, Cheryl Cohen Effron and Blair Effron, and Al and Kathy Hubbard. Corporate funding is provided by Stephens Inc. and Pfizer Inc.

New York Times columnist Frank Bruni sits down with Margaret Hoover to talk about college protests, grievance politics, and how to restore humility in a fractured country. Bruni, author of “The Age of Grievance” and a professor at Duke University, discusses the roots of anti-Israel sentiment on campuses and the double standards behind progressive speech codes. He also addresses the rise of a culture of victimhood on the right and explains how grievances manifest differently across the political spectrum. Bruni touches on activists' response to the arrest of NBA player Brittney Griner in Russia, the “revenge tour” of Prince Harry and Meghan Markle, and what Gen Z social justice warriors should learn from the success of the campaign for marriage equality.  He also looks ahead to a pivotal presidential election and assesses how the dueling grievances of the left and right could impact the campaign. Support for “Firing Line for Margaret Hoover” is provided by Robert Granieri, Vanessa and Henry Cornell, The Fairweather Foundation, The Tepper Foundation, Peter and Mary Kalikow, The Asness Family Foundation, The Beth and Ravenel Curry Foundation, Kathleen and Andrew McKenna through The McKenna Family Foundation, Charles R. Schwab, The Eric and Wendy Schmidt Fund for Strategic Innovation, Pritzker Military Foundation on behalf of the Pritzker Military Museum and Library, The Rosalind P. Walter Foundation, Damon Button, Craig Newmark Philanthropies, The Marc Haas Foundation, Roger and Susan Hertog, Cheryl Cohen Effron and Blair Effron, and Al and Kathy Hubbard. Corporate funding is provided by Stephens Inc. and Pfizer Inc.

Margaret Hoover sits down with Maricopa County Recorder Stephen Richer – a Republican election official in Arizona's most populous county – to discuss the new indictment of allies of Donald Trump for their fake elector scheme in 2020 and how he's preparing for the 2024 election. Richer recalls the “unrelenting” pressure that Arizona officials faced to overturn the 2020 election results and praises figures like former Arizona House Speaker Rusty Bower for resisting the president's demands. He addresses how Republicans have responded to the indictment and whether Trump should also be held accountable for his actions in Arizona. Richer, who is suing Republican Senate candidate Kari Lake for defamation, talks about the harassment, threats, and conspiracy theories he has confronted and how defending the integrity of Arizona's elections has alienated him from many in his party. He also explains why he will blame Lake and Trump if anyone in his office is harmed by election deniers. Richer tells Hoover how he is working to bolster confidence in this November's election as he faces a far-right primary challenge himself, and he reflects on his place in the Republican Party and his future in public service. Support for “Firing Line for Margaret Hoover” is provided by Robert Granieri, Vanessa and Henry Cornell, The Fairweather Foundation, The Tepper Foundation, Peter and Mary Kalikow, The Asness Family Foundation, The Beth and Ravenel Curry Foundation, Kathleen and Andrew McKenna through The McKenna Family Foundation, Charles R. Schwab, The Eric and Wendy Schmidt Fund for Strategic Innovation, Pritzker Military Foundation on behalf of the Pritzker Military Museum and Library, The Rosalind P. Walter Foundation, Damon Button, Craig Newmark Philanthropies, Roger and Susan Hertog, Cheryl Cohen Effron and Blair Effron, and Al and Kathy Hubbard. Corporate funding is provided by Stephens Inc. and Pfizer Inc.

Immunotherapy is a type of novel cancer therapy that leverages the body's own immune system to target cancer cells. In this episode, we focused on the most common type of immunotherapy: immune checkpoint inhibitors or ICIs. ICIs are monoclonal antibodies targeting immune “checkpoints” or brakes to enhance T-cell recognition against tumors. ICI has become a pillar in cancer care, with over 100 approvals and 5,000 ongoing trials. ICIs can lead to non-specific activation of the immune system, causing off-target adverse events such as cardiotoxicities. ICI-related myocarditis, though less common, can be fatal in 30% of cases. Clinical manifestations vary but can include chest pain, dyspnea, palpitations, heart failure symptoms, and arrhythmias. Diagnosis involves echocardiography, cardiac MRI, and endomyocardial biopsy. Treatment includes high-dose corticosteroids with potential additional immunosuppressants. Baseline EKG and troponin are recommended before ICI initiation, but routine surveillance is not advised. Subclinical myocarditis is a challenge, with unclear management implications. So let's dive in and learn about cardiotoxicity of novel immunotherapies with Drs. Giselle Suero (series co-chair), Evelyn Song (episode FIT lead), Daniel Ambinder (CardioNerds co-founder), and Tomas Neilan (faculty expert). Audio editing by CardioNerds Academy Intern, Dr. Maryam Barkhordarian. This episode is supported by a grant from Pfizer Inc. This CardioNerds Cardio-Oncology series is a multi-institutional collaboration made possible by contributions of stellar fellow leads and expert faculty from several programs, led by series co-chairs, Dr. Giselle Suero Abreu, Dr. Dinu Balanescu, and Dr. Teodora Donisan.  CardioNerds Cardio-Oncology PageCardioNerds Episode PageCardioNerds AcademyCardionerds Healy Honor Roll CardioNerds Journal ClubSubscribe to The Heartbeat Newsletter!Check out CardioNerds SWAG!Become a CardioNerds Patron! Pearls and Quotes - Cardiotoxicity of Novel Immunotherapies Immune checkpoint inhibitors (ICI) play a crucial role in current oncology treatment by enhancing T-cell recognition against tumors. ICI-related cardiac immune-related adverse events (iRAEs) include myocarditis, heart failure, stress-cardiomyopathy, conduction abnormalities, venous thrombosis, pericardial disease, vasculitis, and atherosclerotic-related events. ICI myocarditis can be fatal; thus, prompt recognition and treatment is crucial. Management includes cessation of the ICI and treatment with corticosteroids and potentially other immunosuppressants. Close monitoring and collaboration with cardiology and oncology are crucial. Rechallenging patients with immunotherapies after developing an iRAE is controversial and requires careful consideration of risks and benefits, typically with the involvement of a multidisciplinary team. Show notes - Cardiotoxicity of Novel Immunotherapies What are immune checkpoint inhibitors (ICIs)? ICIs are monoclonal antibodies used to enhance the body's immune response against cancer cells. Currently, there are four main classes of FDA-approved ICIs: monoclonal antibodies blocking cytotoxic T lymphocyte antigen-4 (CTLA-4), programed cell death protein-1 (PD-1), lymphocyte-activation gene 3 (LAG3), and programmed cell death ligand-1 (PD-L1). ICIs can lead to non-specific activation of the immune system, potentially causing off-target adverse events in various organs, including the heart, leading to myocarditis.    The mechanisms of cardiac iRAEs are not fully understood, but they are believed to involve T-cell activation against cardiac antigens, which leads to inflammation and tissue damage.  What are the cardiotoxicities related to ICI therapies? ICI-related cardiac immune-related adverse events (iRAEs) include myocarditis, heart failure, stress-cardiomyopathy, conduction abnormalities, venous thrombosis, pericardial disease, vasculitis,

As Donald Trump's first criminal trial begins, Margaret Hoover sits down with NYU law professor Melissa Murray to discuss the historic proceedings and what prosecuting a former president means for America. Murray, co-host of the Strict Scrutiny podcast, breaks down the charges filed by Manhattan DA Alvin Bragg, addresses the challenges of selecting an impartial jury, and responds to Trump's complaints that he has been mistreated by the justice system. Murray, who co-wrote a book about the Trump indictments with former federal prosecutor Andrew Weissmann, comments on the latest developments in the former presidents' three other criminal cases and explains why they might not go to trial before the election. She also previews Supreme Court oral arguments related to January 6th and Trump's claim of absolute immunity, and she reacts to calls from the left for the retirement of Justice Sonia Sotomayor, for whom she once clerked. Support for “Firing Line for Margaret Hoover” is provided by Robert Granieri, Vanessa and Henry Cornell, The Fairweather Foundation, The Tepper Foundation, Peter and Mary Kalikow, The Asness Family Foundation, The Beth and Ravenel Curry Foundation, Kathleen and Andrew McKenna through The McKenna Family Foundation, Charles R. Schwab, The Eric and Wendy Schmidt Fund for Strategic Innovation, Pritzker Military Foundation on behalf of the Pritzker Military Museum and Library, The Rosalind P. Walter Foundation, Damon Button, Craig Newmark Philanthropies, Roger and Susan Hertog, Cheryl Cohen Effron and Blair Effron, and Al and Kathy Hubbard. Corporate funding is provided by Stephens Inc. and Pfizer Inc.

Podcasting has exploded in the last 5 years, with every celebrity, brand, and influencer investing in audio. It's estimated that 144MM people in the U.S. listen to a podcast monthly. With scale and an ability to build audience connections, podcasts have become effective at communicating complex information in a digestible way–making them perfect for sharing science-based stories. Many have heard the term "gene therapy," but how many know what it means? How do you explain the science behind artificial intelligence or designing the Mars Rover? Audio allows us to do this, while enhancing the impact of science communications. Join the Pfizer Podcast team, NASA, UT Austin, and Wonder Media Network as they share their audio expertise and accessible approach to scientific storytelling.Featured experts:Shira Atkins, CRO & Co-Founder, Wonder Media NetworkEllen Gerstein, Head Of Digital Communications, Pfizer Inc.Katie Konans, Audio Storytelling Lead, NASAKristen Wynn, Program Manager, The University of Texas at Austin, Dell Medical School, Livestrong Cancer InstitutesThis episode was recorded live in Austin, TX on Monday March 11 as part of Pfizer's takeover of the South by Southwest podcasting lounge. 

Coleman Hughes, author of “The End of Race Politics,” joins Margaret Hoover to lay out his argument against race-based policies and in favor of a colorblind approach. Hughes, host of the Conversations with Coleman podcast, traces the roots of his colorblind philosophy from the Civil War through the civil rights era, making the case that leaders like Martin Luther King Jr. and Bayard Rustin would have opposed the views of today's anti-racist activists. The descendant of a slave, Hughes tells Hoover why he rejects the notion of inherited trauma and why he believes class-based policies are better suited to combating inequality than race-based ones like affirmative action. He explains why he calls scholars like Robin DiAngelo and Ibram X. Kendi “neoracists” and why he welcomes the backlash against diversity, equity, and inclusion initiatives, but he distances himself from prominent figures on the right like Donald Trump. Hughes also defends his recent Free Press column arguing that Derek Chauvin should have been acquitted of killing George Floyd. Support for “Firing Line for Margaret Hoover” is provided by Robert Granieri, Vanessa and Henry Cornell, The Fairweather Foundation, The Tepper Foundation, Peter and Mary Kalikow, The Asness Family Foundation, The Beth and Ravenel Curry Foundation, Kathleen and Andrew McKenna through The McKenna Family Foundation, Charles R. Schwab, The Eric and Wendy Schmidt Fund for Strategic Innovation, Pritzker Military Foundation on behalf of the Pritzker Military Museum and Library, The Rosalind P. Walter Foundation, Damon Button, Craig Newmark Philanthropies, Roger and Susan Hertog, Cheryl Cohen Effron and Blair Effron, and Al and Kathy Hubbard. Corporate funding is provided by Stephens Inc. and Pfizer Inc.

Futurist Ari Wallach joins Margaret Hoover to discuss “A Brief History of the Future,” his new PBS series exploring the ideas and technologies that could help humanity build better tomorrows. Wallach reflects on the “intertidal” moment society currently faces and explains why he believes decisions made in the years ahead will have ramifications for generations to come. He assesses the implications of emerging tools like artificial intelligence and the challenge posed by humanity's innate negativity bias. He calls for “cathedral thinking” to develop long-term solutions to the world's most pressing problems, and he weighs in on Elon Musk's vision for Mars exploration. Wallach explains why “protopias” are preferable to utopias, details what it takes to become great ancestors to our descendants, and reveals what ultimately gives him hope for the future. Support for “Firing Line for Margaret Hoover” is provided by Robert Granieri, Vanessa and Henry Cornell, The Fairweather Foundation, The Tepper Foundation, Peter and Mary Kalikow, The Asness Family Foundation, The Beth and Ravenel Curry Foundation, Kathleen and Andrew McKenna through The McKenna Family Foundation, Charles R. Schwab, The Eric and Wendy Schmidt Fund for Strategic Innovation, Pritzker Military Foundation on behalf of the Pritzker Military Museum and Library, The Rosalind P. Walter Foundation, Damon Button, Craig Newmark Philanthropies, Roger and Susan Hertog, Cheryl Cohen Effron and Blair Effron, and Al and Kathy Hubbard. Corporate funding is provided by Stephens Inc. and Pfizer Inc.

Margaret Hoover sits down with social psychologist Jonathan Haidt to discuss how social media and smartphones have rewired childhood and put the mental health of a generation of kids at risk. Haidt, author of “The Anxious Generation,” argues a surge in anxiety and depression among Gen Z is a consequence of constant smartphone use that has crowded out traditional forms of play since 2010, and he explains how mental illness has manifested differently in girls and boys.  The NYU professor and father details his proposals for changing norms of parenting and eliminating smartphones in elementary and middle schools, and he addresses the role of Congress in creating this problem–and potentially helping to solve it. Haidt tells Hoover about his “Free the Anxious Generation” movement, rebuts critics who say he overstates the evidence of a link between phone use and mental health, and explains why he considers TikTok “possibly the worst consumer product ever invented.” Support for “Firing Line for Margaret Hoover” is provided by Robert Granieri, Vanessa and Henry Cornell, The Fairweather Foundation, The Tepper Foundation, Peter and Mary Kalikow, The Asness Family Foundation, The Beth and Ravenel Curry Foundation, Kathleen and Andrew McKenna through The McKenna Family Foundation, Charles R. Schwab, The Eric and Wendy Schmidt Fund for Strategic Innovation, Pritzker Military Foundation on behalf of the Pritzker Military Museum and Library, The Rosalind P. Walter Foundation, Damon Button, Craig Newmark Philanthropies, Roger and Susan Hertog, Cheryl Cohen Effron and Blair Effron, and Al and Kathy Hubbard. Corporate funding is provided by Stephens Inc. and Pfizer Inc.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/JSU865. CME/MOC credit will be available until March 22, 2025.The “Immunosurge” Continues: Moving in Leaps and Bounds to Expand the Role and Impact of Immunotherapy in Metastatic, Locally Advanced, and Early-Stage NSCLC In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerSandip Patel, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amgen Inc; AstraZeneca; BeiGene, Inc.; Bristol Myers Squibb; Certis USA L.L.C.; Genentech, Inc.; Illumina, Inc.; Jazz Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Natera, Inc.; Pfizer Inc.; and Tempus.Grant/Research Support from Amgen Inc; AstraZeneca/MedImmune, Inc.; A2BIO; Bristol Myers Squibb; Fate Therapeutics; F. Hoffmann-La Roche Ltd/Genentech, Inc.; Gilead Sciences, Inc.; IOVANCE Biotherapeutics, Inc.; Lilly; Merck & Co., Inc.; and Pfizer Inc.Faculty/PlannerTina Cascone, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Bristol Myers Squibb; Genentech, Inc.; Merck & Co., Inc.; Pfizer Inc.; and Regeneron Pharmaceuticals Inc.Grant/Research Support from AstraZeneca and Bristol Myers Squibb.Faculty/PlannerJohn V. Heymach, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; AnHeart Therapeutics; ArriVent Biopharma; AstraZeneca; BioCurity Pharmaceuticals; BioNTech SE; Blueprint Medicines Corporation; Boehringer Ingelheim International GmbH; Bristol Myers Squibb; Chugai Pharmaceutical Co., Ltd.; Curio Science; DAVA Oncology; EMD Serono, Inc.; F. Hoffmann-La Roche Ltd; Genentech, Inc.; GlaxoSmithKline; IDEOlogy Health; Immunocore Ltd; Janssen Biotech; Janssen Pharmaceuticals, Inc.; Lilly; Mirati Therapeutics, Inc.; Novartis Pharmaceuticals Corporation; Oncocyte Corporation; RefleXion; Regeneron Pharmaceuticals Inc.; Sandoz Group AG; sanofi-aventis U.S. LLC; Spectrum Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; uniQure NV; and Venn Biosciences.Grant/Research Support from AstraZeneca; Boehringer Ingelheim International GmbH; Spectrum Pharmaceuticals, Inc.; Mirati Therapeutics, Inc.; Bristol Myers Squibb; and Takeda Pharmaceutical Company Limited.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/JSU865. CME/MOC credit will be available until March 22, 2025.The “Immunosurge” Continues: Moving in Leaps and Bounds to Expand the Role and Impact of Immunotherapy in Metastatic, Locally Advanced, and Early-Stage NSCLC In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerSandip Patel, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amgen Inc; AstraZeneca; BeiGene, Inc.; Bristol Myers Squibb; Certis USA L.L.C.; Genentech, Inc.; Illumina, Inc.; Jazz Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Natera, Inc.; Pfizer Inc.; and Tempus.Grant/Research Support from Amgen Inc; AstraZeneca/MedImmune, Inc.; A2BIO; Bristol Myers Squibb; Fate Therapeutics; F. Hoffmann-La Roche Ltd/Genentech, Inc.; Gilead Sciences, Inc.; IOVANCE Biotherapeutics, Inc.; Lilly; Merck & Co., Inc.; and Pfizer Inc.Faculty/PlannerTina Cascone, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Bristol Myers Squibb; Genentech, Inc.; Merck & Co., Inc.; Pfizer Inc.; and Regeneron Pharmaceuticals Inc.Grant/Research Support from AstraZeneca and Bristol Myers Squibb.Faculty/PlannerJohn V. Heymach, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; AnHeart Therapeutics; ArriVent Biopharma; AstraZeneca; BioCurity Pharmaceuticals; BioNTech SE; Blueprint Medicines Corporation; Boehringer Ingelheim International GmbH; Bristol Myers Squibb; Chugai Pharmaceutical Co., Ltd.; Curio Science; DAVA Oncology; EMD Serono, Inc.; F. Hoffmann-La Roche Ltd; Genentech, Inc.; GlaxoSmithKline; IDEOlogy Health; Immunocore Ltd; Janssen Biotech; Janssen Pharmaceuticals, Inc.; Lilly; Mirati Therapeutics, Inc.; Novartis Pharmaceuticals Corporation; Oncocyte Corporation; RefleXion; Regeneron Pharmaceuticals Inc.; Sandoz Group AG; sanofi-aventis U.S. LLC; Spectrum Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; uniQure NV; and Venn Biosciences.Grant/Research Support from AstraZeneca; Boehringer Ingelheim International GmbH; Spectrum Pharmaceuticals, Inc.; Mirati Therapeutics, Inc.; Bristol Myers Squibb; and Takeda Pharmaceutical Company Limited.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Margaret Hoover hosts a forum at Hofstra University on whether America should abolish the Electoral College with writers Jesse Wegman and Trent England. Wegman, author of “Let the People Pick the President” and a member of The New York Times editorial board, makes the case that the current system is unfair and undemocratic, empowering a handful of swing states to decide who leads the whole country. England, who founded Save Our States and wrote “Why We Must Defend the Electoral College,” argues the Electoral College makes presidential campaigns both more national and more granular at the same time, forcing candidates to appeal to diverse factions of voters across the country who otherwise would have little influence. Wegman and England discuss the history of the Electoral College, the intent of the nation's founders, and how it all relates to slavery. They also debate the merits of a national popular vote and whether other reforms are possible, and they take questions from the student audience. Support for “Firing Line for Margaret Hoover” is provided by Robert Granieri, Vanessa and Henry Cornell, The Fairweather Foundation, The Tepper Foundation, Peter and Mary Kalikow, The Asness Family Foundation, The Beth and Ravenel Curry Foundation, Kathleen and Andrew McKenna through The McKenna Family Foundation, Charles R. Schwab, The Eric and Wendy Schmidt Fund for Strategic Innovation, Pritzker Military Foundation on behalf of the Pritzker Military Museum and Library, The Rosalind P. Walter Foundation, Damon Button, Craig Newmark Philanthropies, Roger and Susan Hertog, Cheryl Cohen Effron and Blair Effron, and Al and Kathy Hubbard. Corporate funding is provided by Stephens Inc. and Pfizer Inc.

In a special Firing Line forum recorded before a student audience at Hofstra University, Margaret Hoover talks to conservatives Amanda Carpenter and Mike Gonzalez about the potential ramifications of another Donald Trump presidency. Carpenter, a writer and editor for Protect Democracy, believes a second Trump term would be far more damaging than the first, citing the former president's threats to punish his enemies and promises to reward his allies. She warns the institutional guardrails that constrained him in the past would be weakened or eliminated in a new administration. Gonzalez, who contributed to the Heritage Foundation's Project 2025 guidebook for the next conservative president, downplays concerns Trump would abuse power if he returned to office. He maintains the U.S. and the world were better off during Trump's first three years in office than in President Biden's first three years. Carpenter and Gonzalez discuss Trump's plans for immigration, foreign policy, and rooting out the “deep state” in the federal bureaucracy. Responding to questions from students, they also address the future of the Republican Party and what to expect in an eventual post-Trump America.  Mike Gonzalez serves as a Senior Fellow at The Heritage Foundation. The Heritage Foundation is listed for identification purposes only; no endorsement of a candidate by the organization is implied. Support for “Firing Line for Margaret Hoover” is provided by Robert Granieri, Vanessa and Henry Cornell, The Fairweather Foundation, The Tepper Foundation, Peter and Mary Kalikow, The Asness Family Foundation, The Beth and Ravenel Curry Foundation, Kathleen and Andrew McKenna through The McKenna Family Foundation, Charles R. Schwab, Pritzker Military Foundation on behalf of the Pritzker Military Museum and Library, The Rosalind P. Walter Foundation, Damon Button, Craig Newmark Philanthropies, Roger and Susan Hertog, Cheryl Cohen Effron and Blair Effron, and Al and Kathy Hubbard. Corporate funding is provided by Stephens Inc. and Pfizer Inc.

Margaret Hoover sits down with Jared Cohen, author of “Life After Power: Seven Presidents and Their Search for Purpose Beyond the White House,” to discuss the unique role of the post-presidency in American democracy. Cohen's book explores how different ex-presidents have handled being out of power from Thomas Jefferson to George W. Bush. He explains why examining the lives of former presidents interested him and what can be learned from their experiences. He reflects on John Quincy Adams' “second act” as an abolitionist congressman, contrasts Herbert Hoover's reputation as president with the notable accomplishments of his post-presidency, and details how Jimmy Carter redefined the position of ex-president for modern times. Cohen explains how Grover Cleveland's return to the White House could offer a cautionary tale for a second Donald Trump term, and he reflects on what it will mean to have more ex-presidents alive at the same time in the decades to come. Support for “Firing Line for Margaret Hoover” is provided by Robert Granieri, Stephens Inc., Vanessa and Henry Cornell, The Fairweather Foundation, The Tepper Foundation, Peter and Mary Kalikow, The Asness Family Foundation, The Beth and Ravenel Curry Foundation, Kathleen and Andrew McKenna through The McKenna Family Foundation, Pfizer Inc., Charles R. Schwab, Pritzker Military Foundation on behalf of the Pritzker Military Museum and Library, The Rosalind P. Walter Foundation, Damon Button, Craig Newmark Philanthropies, Roger and Susan Hertog, Cheryl Cohen Effron and Blair Effron, and Al and Kathy Hubbard.

Entrepreneur Sheila Johnson–who co-founded BET and went on to become America's first Black female billionaire–sits down with Margaret Hoover to discuss her memoir and the personal and professional obstacles she has overcome to achieve success. Johnson, who recently released “Walk Through Fire: A Memoir of Love, Loss, and Triumph,” reflects on her childhood and what she describes as an abusive first marriage to Bob Johnson, with whom she launched Black Entertainment Television in the early days of cable. She explains the original vision behind BET and the role she believes it could still play in society today. Johnson used her profits from the 2001 sale of BET to open Salamander Resort in Middleburg, Virginia, the first in a chain of luxury hotels. She also purchased a stake in the WNBA's Washington Mystics, as well as the Washington Capitals and the Washington Wizards. She reflects on the massive pay gap between the WNBA and the NBA and what can be done about it. Johnson, a supporter of President Joe Biden, assesses the stakes of the 2024 election and details her fears for a second Trump term. The prominent philanthropist also comments on the fallout from the Supreme Court's affirmative action decision and the need to create new opportunities for students of color. Support for “Firing Line for Margaret Hoover” is provided by Robert Granieri, Stephens Inc., Vanessa and Henry Cornell, The Fairweather Foundation, The Tepper Foundation, Peter and Mary Kalikow, The Asness Family Foundation, The Beth and Ravenel Curry Foundation, Kathleen and Andrew McKenna through The McKenna Family Foundation, Pfizer Inc., Charles R. Schwab, Pritzker Military Foundation on behalf of the Pritzker Military Museum and Library, The Rosalind P. Walter Foundation, Damon Button, Craig Newmark Philanthropies, Roger and Susan Hertog, Cheryl Cohen Effron and Blair Effron, and Al and Kathy Hubbard.

CardioNerds co-founder Dr. Dan Ambinder, series chair Dr. Teodora Donisan, and Dr. Sukriti Banthiya discuss cardiac tumors with Dr. Juan Lopez-Mattei, a nationally recognized expert in the fields of cardio-oncology and the director of cardiac imaging at the Lee Health Heart Institute. Here, we explore the topic of cardiac tumors, with a focus on distinguishing between primary and secondary tumors. We delve into the symptoms, diagnostic methods, and treatment options. Show notes were drafted by Dr. Sukriti Banthiya and episode audio was edited by CardioNerds Intern and student Dr. Diane Masket. This episode is supported by a grant from Pfizer Inc. This CardioNerds Cardio-Oncology series is a multi-institutional collaboration made possible by contributions of stellar fellow leads and expert faculty from several programs, led by series co-chairs, Dr. Giselle Suero Abreu, Dr. Dinu Balanescu, and Dr. Teodora Donisan.  CardioNerds Cardio-Oncology PageCardioNerds Episode PageCardioNerds AcademyCardionerds Healy Honor Roll CardioNerds Journal ClubSubscribe to The Heartbeat Newsletter!Check out CardioNerds SWAG!Become a CardioNerds Patron! Pearls and Quotes - Cardiac Tumors Keep it simple when approaching an intracardiac mass; start with transthoracic echocardiography (TTE) and use transesophageal echocardiography (TEE) or cardiac magnetic resonance (CMR) based on the clinical context. Use TEE when suspecting valvular vegetations or thrombi & CMR for intracavitary cardiac masses. Cardiac tumors can manifest with a variety of symptoms; however, they are more commonly diagnosed as an incidental finding! When faced with the dilemma of selecting the most suitable imaging modality for evaluating a cardiac mass, consider the following hierarchy: begin with TTEas the first choice, followed by CMR. If the patient cannot undergo CMR, the next step is cardiac computed tomography (CT) or Fluorodeoxyglucose F18 positron emission tomography (FDG-PET). TEE is especially useful for the evaluation of small, highly mobile cardiac masses! Imaging cannot substitute a tissue diagnosis of cardiac masses. However, in cases of advanced malignancy, it may not always be necessary. Show notes - Cardiac Tumors Segment One: A big “picture” Approach to Cardiac Tumors Let's start with an overview of cardiac masses Neoplastic vs non-neoplasticNeoplastic lesions can be further classified into Primary Cardiac Tumors (PCT's) & Secondary Cardiac Tumor (SCT's)A majority of PCTs are benign (up to 90%!); however, rarely, they may be malignant. SCTs are more common than PCTs, and, by definition, they are malignant tumors. Now, let's look at the tools you can use to aid with the diagnosis of cardiac masses… Step 1: Investigate the cardiac mass initially with TTE. Step 2: Collect clues through history-taking & examination.If suspecting valvular vegetations (as in infective endocarditis!) or left atrial appendage thrombus, characterize the mass further with TEE.Consider the possibility of metastatic cardiac tumors in patients with a known malignancy, as they are more common than primary cardiac tumors. In cases where it is uncertain if the mass is a cardiac tumor or thrombus, use CMR to differentiate the two entities. Some findings on TTE that support the presence of a thrombus include left ventricular dysfunction with segmental wall motion abnormalities and/or apical aneurysm as these result in local pockets of stasis (think: Virchow's triad) Step 3: Put it all together! Think about whether a tissue biopsy will be needed. If yes, determine whether a negative margin or open biopsy will be required. Segment Two: Symptoms, Symptoms, Symptoms! Cardiac tumors may be symptomatic and present in the 3 key ways as outlined below (Think COD

Retired Gen. David Petraeus sits down with Margaret Hoover to discuss retaliation for a fatal drone attack on U.S. troops in Jordan, as well as the latest developments in the wars in Gaza and Ukraine. Petraeus, co-author of Conflict: The Evolution of Warfare from 1945 to Ukraine, offers insight into the Biden administration's deliberations on a response to the attack by an Iran-backed militia and why restoring deterrence against Iran is crucial. The former four-star general, who led troops in Iraq and Afghanistan, reflects on the “fiendishly difficult” challenges Israel faces in its effort to destroy Hamas and the importance of planning to rebuild Gaza after the war. He comments on the controversy over UN relief workers allegedly assisting Hamas and the status of ongoing hostage negotiations. Petraeus also addresses resistance to continued aid for Ukraine in Congress, and he explains how the conflict relates to preventing a potentially catastrophic war in China. Support for “Firing Line for Margaret Hoover” is provided by Robert Granieri, Stephens Inc., Vanessa and Henry Cornell, The Fairweather Foundation, The Tepper Foundation, Peter and Mary Kalikow, The Asness Family Foundation, The Beth and Ravenel Curry Foundation, Kathleen and Andrew McKenna through The McKenna Family Foundation, Pfizer Inc., Charles R. Schwab, The Rosalind P. Walter Foundation, Damon Button, Craig Newmark Philanthropies, Roger and Susan Hertog, Cheryl Cohen Effron and Blair Effron, and Al and Kathy Hubbard.

Deborah Lipstadt, the State Department's special envoy to monitor and combat antisemitism, joins Margaret Hoover to talk about the surge of hatred against Jews worldwide since October 7th and why she considers it a threat to democracy. Lipstadt, who has studied antisemitism and Holocaust denialism for decades, details the double standard she sees in the muted response to the Hamas attack from organizations and corporations that have quickly spoken out against racism and other injustices in the past. She also questions why women's rights groups have not been more vocal about Hamas' use of sexual violence against women. She reflects on the attitudes driving protests against Israel on college campuses and elsewhere, as well as the prospect that diplomatic progress in the Middle East could quell hostility toward Jews. In addition, Lipstadt addresses China's promotion of antisemitism, dissent within the Biden administration over the war in Gaza, and allegations that Israel is committing genocide.  Support for “Firing Line for Margaret Hoover” is provided by Robert Granieri, Stephens Inc., Vanessa and Henry Cornell, The Fairweather Foundation, The Tepper Foundation, Peter and Mary Kalikow, The Asness Family Foundation, The Beth and Ravenel Curry Foundation, Kathleen and Andrew McKenna through The McKenna Family Foundation, Pfizer Inc., Charles R. Schwab, The Rosalind P. Walter Foundation, Damon Button, Craig Newmark Philanthropies, Roger and Susan Hertog, Cheryl Cohen Effron and Blair Effron, and Al and Kathy Hubbard.

New Hampshire Governor Chris Sununu sits down with Margaret Hoover in Concord to make his case for Nikki Haley ahead of next week's pivotal Republican presidential primary. Sununu explains why he believes the former South Carolina governor is well-positioned to take on Donald Trump despite Trump's decisive victory in Iowa and how his state's independent streak and history of supporting underdogs could give her an edge. The fourth-term governor contrasts Haley's experience and electability with Trump, discusses their policy proposals, and reflects on what the outcome of the race could mean for the future of the GOP. Despite his endorsement of Haley and his concerns about January 6th, Sununu defends his commitment to supporting Trump if he is the Republican nominee, and he argues a second Trump presidency would be better for the country than four more years of Joe Biden. Support for “Firing Line for Margaret Hoover” is provided by Robert Granieri, Stephens Inc., Vanessa and Henry Cornell, The Fairweather Foundation, The Tepper Foundation, Peter and Mary Kalikow, The Asness Family Foundation, The Beth and Ravenel Curry Foundation, Kathleen and Andrew McKenna through The McKenna Family Foundation, Pfizer Inc., Charles R. Schwab, The Rosalind P. Walter Foundation, Damon Button, Craig Newmark Philanthropies, Roger and Susan Hertog, Cheryl Cohen Effron and Blair Effron, and Al and Kathy Hubbard.

Texas Republican Rep. Tony Gonzales sits down with Margaret Hoover to talk about the record influx of migrants at the southern border and what it will take for Washington to confront the crisis. Gonzales, whose district includes nearly half the U.S.-Mexico border, explains why the surge of migration is happening now, how it is different from previous upticks, and how its economic and social impact is increasingly being felt across the country. He details his proposals to improve border security and protect legal immigration, as well as the challenge of convincing members of both parties to set aside politics and pursue real solutions. He also assesses the status of bipartisan immigration negotiations in the Senate. Gonzales discusses GOP efforts to impeach Homeland Security Secretary Alejandro Mayorkas, his endorsement of Donald Trump for president in 2024, and his own reelection race.  Support for “Firing Line for Margaret Hoover” is provided by Robert Granieri, Stephens Inc., Vanessa and Henry Cornell, The Fairweather Foundation, The Tepper Foundation, Peter and Mary Kalikow, The Asness Family Foundation, The Beth and Ravenel Curry Foundation, Kathleen and Andrew McKenna through The McKenna Family Foundation, Pfizer Inc., Charles R. Schwab, The Rosalind P. Walter Foundation, Damon Button, Craig Newmark Philanthropies, Roger and Susan Hertog, Cheryl Cohen Effron and Blair Effron, and Al and Kathy Hubbard.

CardioNerds co-founder Dr. Dan Ambinder, series chair Dr. Giselle Suero Abreu, and episode FIT Lead Dr. Rachel Ohman discuss disparities in cardiooncology with Dr. Javier Gomez Valencia, the Director of Cardio-Oncology services at John H. Stronger Jr. Hospital of Cook County. Dr. Rachel Ohman drafted show notes. Audio editing by student doctor Shivani Reddy. A disproportionate burden of both cancer and cardiovascular disease affects racial and ethnic minority groups as well as lower-income communities. Similar patterns of vulnerability exist among cancer survivors with cardiovascular disease, although further investigation in these subpopulations is needed. We discuss a comprehensive approach to the cardio-oncology patient, our current understanding of the social and structural determinants of disparities in cardio-oncology populations, and other contributions to inequity in the field. Given the growing population of cancer survivors and limited accessibility to cardio-oncology specialists, these topics are of critical importance to anyone caring for cancer patients who have or are at risk for cardiovascular disease. This episode is supported by a grant from Pfizer Inc. This CardioNerds Cardio-Oncology series is a multi-institutional collaboration made possible by contributions of stellar fellow leads and expert faculty from several programs, led by series co-chairs, Dr. Giselle Suero Abreu, Dr. Dinu Balanescu, and Dr. Teodora Donisan.  CardioNerds Cardio-Oncology PageCardioNerds Episode PageCardioNerds AcademyCardionerds Healy Honor Roll CardioNerds Journal ClubSubscribe to The Heartbeat Newsletter!Check out CardioNerds SWAG!Become a CardioNerds Patron! Pearls and Quotes - Disparities in CardioOncology Social and structural determinants of health are drivers of cardiovascular and cancer disparities. Existing data on cardiotoxicity outcomes suggests these determinants also contribute to disparities in cardio-oncology. Assessing social and structural determinants of health should be a routine part of evaluating a patient with an active or prior history of cancer. Customs, country of origin, and immigration status matter. Differential risk profiles among Hispanic/Latinx sub-populations require further investigation. Black patients, particularly black women with breast cancer, have elevated morbidity and mortality from cardiotoxicity. Data suggest contributions from social determinants of health. Representation in clinical trials must be diversified for applicability to our diverse patient populations. Concerted efforts should be made to recruit diverse clinical trial participants and help patients from diverse communities effectively participate in the research process, contributing to the advancement of science. Show notes - Disparities in CardioOncology How do you approach the evaluation of a new patient in cardio-oncology? How do social and structural determinants of health impact treatment-associated cardiotoxicity? The evaluation of a new patient should include an assessment of a patient's intrinsic risk factors, risks associated with cancer treatment, and consideration of cardioprotective therapeutic strategies Social and structural vulnerabilities should also be assessed routinely as a part of risk stratification. Providers should take stock of a patient's demographic (e.g., race/ethnicity, gender), socioeconomic (e.g., occupation, insurance status, food security, housing security), environmental (e.g., transportation, proximity to health resources, neighborhood safety), and sociocultural (e.g., psychosocial stressors, discrimination, acculturation) determinants that are in turn modulated by larger systemic forces like structural racism. This comprehensive risk assessment can guide the strategies to mitigate cardiovascular risk before, during, and after cancer treatment. What barriers to cardio-oncology care are unique to the Hispanic/Latinx popula...

CardioNerds (Dr. Daniel Ambinder, Dr. Giselle Suero Abreu, Dr. Kahtan Fadah, and Dr. Colin Blumenthal) discuss arrhythmias in CardioOncology with Dr. Michael Fradley. In this episode, Dr. Michael Fradley joins us in the CardioNerds CardioOncology clinic where he uses his unique dual training in cardio-oncology and electrophysiology to walk us through the complex interplay and management of these disorders. We discuss the incidence and pathophysiology of these arrhythmias, including the link with various cancer treatments, screening and detection, and complex management including rate vs rhythm control in atrial fibrillation, need for anticoagulation, effects on the QTc and so much more. Given the unique challenges with this population we also delve into how this affects their oncology care and how to approach changes to their cancer treatment. Show notes were drafted by Dr. Kahtan Fadah and episode audio was edited by student Dr. Tina Reddy. This episode is supported by a grant from Pfizer Inc. This CardioNerds Cardio-Oncology series is a multi-institutional collaboration made possible by contributions of stellar fellow leads and expert faculty from several programs, led by series co-chairs, Dr. Giselle Suero Abreu, Dr. Dinu Balanescu, and Dr. Teodora Donisan.  CardioNerds Cardio-Oncology PageCardioNerds Episode PageCardioNerds AcademyCardionerds Healy Honor Roll CardioNerds Journal ClubSubscribe to The Heartbeat Newsletter!Check out CardioNerds SWAG!Become a CardioNerds Patron! Pearls and Quotes - Arrhythmias in CardioOncology Arrhythmias are common in cancer patients due to shared risk factors and bi-directional risk between cardiac and oncologic disorders. Many cancer therapeutics can be directly arrhythmogenic or lead to cardiotoxicities that pre-dispose to arrhythmias. Though incidence of arrhythmia can be significant increased with some cancer therapeutics (e.g. ibrutinib), there is not specific data to support proactive ambulatory monitoring for arrhythmia without evidence of clear symptoms. Atrial fibrillation is the most common arrhythmia in cancer patients and management of atrial fibrillation, as well as other tachyarrhythmias, is unchanged from management in non-cancer patients. General principles of when to start anticoagulation or rate vs rhythm control are not significantly different (e.g. still use CHA2DS2-VAsC, monitor for symptoms etc), but providers should be more mindful of drug-drug interactions with cancer therapeutics. Cancer therapeutics as well as common medications used to treat side effects or complications (e.g. antiemetics, antibiotics, etc) can prolong the QT interval and increase risk of Torsades de pointes (TdP). The QTc should be monitored with an ECG for patients on these medications. If a patient does develop a serious arrhythmia like TdP, management is similar to that in non-cancer patients. The goal of arrhythmia management in cardio-oncology is to prevent cardiovascular disease from becoming a barrier to appropriate cancer therapy. Though cancer therapeutics should be temporarily or permanently discontinued in potentially fatal events (e.g TdP from QTc prolonging meds), the overall goal is to manage the arrhythmias appropriately to allow cancer therapeutics to be continued or restarted. Show notes - Arrhythmias in CardioOncology What is the prevalence of arrhythmias in patients with cancer? Arrhythmias are common in patients with cancer due to a multitude of factors. Atrial fibrillation is the most common arrhythmia in this population and occurs in approximately 5% of patients with cancer. The driving forces are multifactorial and include the direct arrhythmogenic effects of cancer therapeutics and cardiotoxicities of cancer therapeutics that make arrhythmogenesis more likely. Additionally, there is a bi-directional link between cancer and cardiac disorders. For example, not only is atrial fibrillation more common in patien...

In this episode, CardioNerds Dr. Daniel Ambinder, Dr. Giselle Suero Abreu, and Dr. Saahil Jumkhawala discuss thromboembolic disease in cardio-oncology with faculty expert Dr. Joshua Levenson, the Associate Program Director of the cardiology fellowship and an Assistant Professor of Medicine at the University of Pittsburg School of Medicine. Venous (VTE) and arterial thromboembolic (ATE) events are precipitants of morbidity and mortality in patients with cancer. Here, we discuss the pathophysiology of thromboembolism, risk factors and epidemiology for ATE and VTE, the role of risk prediction and patient stratification, and the approach to treatment for and prophylaxis of thromboembolic events with anticoagulation. Show notes were drafted by Dr. Saahil Jumkhawala and episode audio was edited by CardioNerds Intern Dr. Tina Reddy. This episode is supported by a grant from Pfizer Inc. This CardioNerds Cardio-Oncology series is a multi-institutional collaboration made possible by contributions of stellar fellow leads and expert faculty from several programs, led by series co-chairs, Dr. Giselle Suero Abreu, Dr. Dinu Balanescu, and Dr. Teodora Donisan.  CardioNerds Cardio-Oncology PageCardioNerds Episode PageCardioNerds AcademyCardionerds Healy Honor Roll CardioNerds Journal ClubSubscribe to The Heartbeat Newsletter!Check out CardioNerds SWAG!Become a CardioNerds Patron! Pearls and Quotes - Thromboembolic Disease in Cardio-oncology Patients with cancer are at higher risk of developing both arterial and venous thromboembolic events compared to the general population. Certain cancer subtypes are associated with a relatively higher risk of developing thromboembolic complications. Anticoagulation type and duration should be dependent on patient characteristics and risk factors, with shared decision-making between the patient and their providers. Subgroups of patients may benefit from more aggressive management of their atherosclerotic cardiovascular risk factors while being treated for cancer to reduce the risk of thromboembolic complications. Show notes - Thromboembolic Disease in Cardio-oncology What are the incidence and main manifestations of thromboembolic events (venous and arterial) in patients with active malignancy? Approximately 10% of outpatients with active cancer have venous thromboembolic events, many of which are asymptomatic. Clinically relevant VTEs are predominantly deep venous thrombosis (DVTs) with pain and/or swelling of the involved extremities or pulmonary emboli (PEs) resulting in chest pain and/or shortness of breath. VTE is the number one preventable cause of death for all hospitalized patients, and the ability to prevent and treat these events is crucial, particularly in high-risk populations such as patients with cancer. Are there any high-risk associations with specific cancer subtypes? Patients with metastatic disease and those receiving chemotherapy are more likely to develop arterial or venous thromboembolic events. Patients with acute myelogenous leukemia (AML) and thrombocytopenic patients are at the lowest risk for thromboembolic events. Multiple myeloma patients on medication such as proteasome inhibitors or lenalidomide appear at particular risk. Patients with localized, early-stage cancers such as breast, prostate, and melanoma are also at lower risk. What are the main risk factors to identify patients at a higher risk of developing thrombotic complications? Patients with a sedentary lifestyle, deconditioning, and undergoing active treatment with chemotherapy are at the highest risk of developing DVT or PE. How should we approach choosing the optimal type and duration of anticoagulation for acute pulmonary embolism (PE) in the setting of malignancy? This remains an area of active research. Historically, patients would receive systemic anticoagulation with heparin followed by warfarin.